{"analyses":[{"ciLowerLimit":"0.361","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.789","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0014","paramType":"Hazard Ratio (HR)","paramValue":"0.533","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Here, NA signifies that upper limit of 95% confidence interval could not be calculated due to the too low number of participants with a rPFS event observed by the time of analysis.","groupId":"OG000","lowerLimit":"13.86","upperLimit":"NA","value":"16.56"},{"groupId":"OG001","lowerLimit":"8.31","upperLimit":"13.80","value":"10.87"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"112"}],"units":"Participants"}],"description":"As per BICR, rPFS is time interval from the date of randomization to radiographic progression or death, whichever occurred first. Radiographic progression was determined by: (1) progression of soft tissue lesions measured by CT or MRI as per RECIST 1.1; (2) Progression of bone lesions observed by bone scan based on PCWG3 criteria. PCWG3 criteria: bone progression was confirmed by subsequent scan \\>=6 weeks later. Week 8 scan was baseline to which all subsequent scans were compared to determine progression. Confirmatory scan \\>=2 new lesions indicate progression; scan does not show \\>=2 new lesions means no progression. If Week 8 scan \\<2 new bone lesions compared to baseline, the initial scan \\>=2 new lesions compared to Week 8 scan indicates progression if confirmed by subsequent scan \\>=6 weeks later.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with metastatic castration-resistant prostate cancer (mCRPC) and BRCA alterations, received niraparib 200 milligrams (mg) capsule in combination with abiraterone acetate 1000 mg tablet orally once daily (QD) and prednisone 5 mg tablet orally twice daily (BID) (total dose 10 mg) in each 28 days treatment cycle starting from Cycle 1 Day 1 up to 29 months. Participants were then followed up for safety up to 5 years after last dose or until death, loss to follow-up, withdrawal of consent, or study termination. Participants were continued to receive niraparib 200 mg and abiraterone acetate 1000 mg plus prednisone 10 mg in the open label extension phase.","id":"OG000","title":"Cohort 1 BRCA Subgroup: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg"},{"description":"Participants with mCRPC and BRCA alterations, received placebo in combination with abiraterone acetate 1000 mg tablet orally QD and prednisone 5 mg tablet orally BID (total dose 10 mg) in each 28 days treatment cycle starting from Cycle 1 Day 1 up to 29 months. Participants were then followed up for safety up to 5 years after last dose or until death, loss to follow-up, withdrawal of consent, or study termination. Participants who received placebo and abiraterone acetate plus prednisone were allowed to cross over to receive niraparib 200 mg and abiraterone acetate 1000 mg plus prednisone 10 mg in the open-label extension phase.","id":"OG001","title":"Cohort 1 BRCA Subgroup: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg"}],"paramType":"MEDIAN","populationDescription":"The randomized analysis set for cohort 1 BRCA subgroup included all randomized participants in Cohort 1 BRCA subgroup. Data for this outcome measure was planned to be collected and analyzed for BRCA subgroup of Cohort 1 only.","reportingStatus":"POSTED","timeFrame":"Up to 32 months","title":"Cohort 1 Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-Free Survival (rPFS) as Assessed by Blinded Independent Central Review (BICR)","type":"PRIMARY","unitOfMeasure":"Months"}